Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
0–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient receives lorlatinib through Pfizer's expanded access program for treatment of ALK+ neuroblastoma.
HCP documentation of at least one tumor assessment of response after patient has had at least one dose of lorlatinib
Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
